Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    2(100%)

    Phase Distribution

    Early Phase 1
    2
    100%

    Phase Distribution

    2

    Early Stage

    0

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Early Phase 1First-in-human
    2(100.0%)

    Highest Phase Reached

    Early Phase 1

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    2

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Active(2)

    Detailed Status

    Recruiting2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    2
    Success Rate
    N/A
    Most Advanced
    Early Phase 1

    Trials by Phase

    Early Phase 12 (100.0%)

    Trials by Status

    recruiting2100%

    Recent Activity

    2 active trials
    Showing 2 of 2
    recruitingearly_phase_1

    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

    NCT06633341
    recruitingearly_phase_1

    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

    NCT06633354

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT06633341Early Phase 1

    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

    Recruiting
    NCT06633354Early Phase 1

    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

    Recruiting

    All 2 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    2